tasquinimod

Phase 2Small molecule

Ipsen

tasquinimod is one of 52 small molecule programs targeting Primary Myelofibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary MyelofibrosisRecruiting

MyelofibrosisRecruiting

Primary MyelofibrosisPhase 2

Recruiting

MyelofibrosisPhase 2

Recruiting

Competition

Competitive Landscape

49 competitors in Myelofibrosis

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

55 2

Ojjaara

GGlaxo Dba Glaxosmithkline

Approved

8 3

Tepadina

Rifadin

Droxia

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Vonjo

4 8

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

3 9

Navitoclax

AbbVie

Phase 3

5 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1/2Recruiting

Myelofibrosis

NCT06605586

Q2 2031

Phase 1/2Recruiting

Primary Myelofibrosis

NCT06327100

Clinical

Trials by Indication[1]

Prostate Cancer6 trials

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

Completed·—·Phase 1·NCT01513733·25 enrolled

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Completed·AActive Biotech AB·Phase 3·NCT01234311·1,245 enrolled

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Terminated· Ipsen logo

Ipsen·Phase 3·NCT02057666·146 enrolled

Show 3 more trials

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT02159950·2 enrolled

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02396368

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Terminated· Ipsen logo

Ipsen·Phase 2·NCT01732549·144 enrolled

Primary Myelofibrosis1 trial

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06327100·33 enrolled

Relapsed or Refractory1 trial

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Terminated·UUniversity of Pennsylvania·Phase 1·NCT04405167·30 enrolled

Gastric Cancer1 trial

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Completed· Ipsen logo

Ipsen·Phase 2·NCT01743469·201 enrolled

Myelofibrosis1 trial

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

Recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 1/2·NCT06605586·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for tasquinimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tasquinimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tasquinimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ipsen

tasquinimod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q2 2031

Trials by Indication[1]

Prostate Cancer6 trials

Primary Myelofibrosis1 trial

Relapsed or Refractory1 trial

Gastric Cancer1 trial

Myelofibrosis1 trial

References

Drug Info

Quick Facts

Related News